Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma by Carolyn Helms | Jun 15, 2023 | Portfolio News
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy by Carolyn Helms | Jun 13, 2023 | Uncategorized
Somatus Expands Multi-State Value-Based Kidney Care Partnership with Kidney Care Center by Carolyn Helms | Jun 8, 2023 | Portfolio News
WelbeHealth Continues Los Angeles Expansion With Opening of New PACE Centers in Rosemead and North Hollywood by Carolyn Helms | Jun 8, 2023 | Uncategorized
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST by Carolyn Helms | May 25, 2023 | Portfolio News
